[1] MARTINEZ J P,SASSE F,BRÖNSTRUP M M,et al.Antiviral drug discovery:broad-spectrum drugs from nature[J].Nat Prod Rep,2015,32(1):29-48.
[2] WANG Y X,LI J X,HU Y M,et al.Ebola vaccines in clinical trial:the promising candidates[J].Human Vacc Immunother,2017,13(1):153-168.
[3] 杜红,赵柳红,覃忠于,等.HIV感染/AIDS住院患者高效抗逆转录病毒治疗中发生骨髓抑制致死亡的影响因素[J].中国药房,2015,26(35):4951-4954.
[4] 陈美钦,王长连.核苷类抗病毒药群体药动学研究及应用[J].海峡药学,2016,28(7):4-7.
[5] DÉBORAH H,SAIK U,ELISABETH R,et al.Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates[J].Antimicrob Agent,2009,53(3):1067-1073.
[6] ELION R,MOLINA J M,RAMN ARRIBAS LPEZ J,et al.A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection[J].J AIDS,2013,63(4):494-497.
[7] 杨庆坤,龙燕,陈典颜,等.PEG-IFN α-2a和利巴韦林联合自拟中药复方治疗慢性丙型肝炎的临床疗效[J].重庆医学,2017,46(32):4533-4536.
[8] 戴兆东,经继生,赵伟.普通干扰素联合利巴韦林治疗1b型丙肝患者疗效分析[J].东南大学学报(医学版),2017,36(6):1002-1004.
[9] KAMATA M,LIU S,LIANG M,et al.Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter[J].Human Gene Therap,2010,21(11):1555-1567.
[10] REGULES J A,BEIGEL J H,PAOLINO K M,et al.A recombinant vesicular stomatitis virus Ebola vaccine[J].N Engl J Med,2017,376(4):330-341.
[11] SHUCHMAN M.Ebola vaccine trial in west Africa faces criticism[J].Lancet,2015,385(9981):1933-1934.
[12] Agnandji S T,Huttner A,Zinser M E,et al.Phase 1 trials of rVSV Ebola vaccine in Africa and Europe[J].N Engl J Med,2016,374(17):1647-1660.
[13] MEDAGLINI D,HARANDI A M,OTTENHOFF T H M,et al.Ebola vaccine R&D:filling the knowledge gaps[J].Sci Transl Med,2015,7(317):317ps24.
[14] FELDMANN H,JONES S M,DADDARIO-DICAPRIO K M,et al.Effective post-exposure treatment of Ebola infection[J].PLoS Pathogens,2007,3(1):e2.
[15] JACOBS M,AARONS E,BHAGANI S,et al.Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents:a case-series of health-care workers[J].Lancet Infect Dis,2015,15(11):1300-1304.
[16] LI A Z,YU J Y,LU M J,et al.A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein[J].Nat Commun,2018,9:3067.
[17] 李静,戎庭军,张铭键,等.TLR7的研究进展[J].浙江临床医学,2015(2):315-317.
[18] HEMMI H,KAISHO T,TAKEUCHI O,et al.Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway[J].Nat Immunol,2002,3(2):196-200.
[19] MARTIN H J,LEE J M,WALLS D,et al.Manipulation of the toll-like receptor 7 signaling pathway by epstein-barr virus[J].J Virol,2007,81(18):9748-9758.
[20] SUNG J A,PATEL S,CLOHOSEY M L,et al.HIV-specific,Ex vivo expanded T cell therapy:feasibility,safety,and efficacy in ART-suppressed HIV-infected individuals[J].Molecul Ther,2018,26(10):2496-2506.
[21] MENDOZA P,GRUELL H,NOGUEIRA L,et al.Combination therapy with anti-HIV-1 antibodies maintains viral suppression[J].Nature,2018,561(7724):479-484.
[22] 赵旭,周辛波,钟武,等.抗病毒药物——法匹拉韦[J].临床药物治疗杂志,2015,13(4):16-20.
[23] SHI F,LI Z,KONG L,et al.Synthesis and crystal structure of 6-fluoro-3-hydroxypyrazine-2-carboxamide[J].Drug Discov Ther,2014,8(3):117-120.